| metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2) | |||||
| mNSCLC - L2 - all population | mNSCLC - L2 - EGFR mutant | mNSCLC - L2 - PDL1 positive | non squamous - mNSCLC - L2 - all population | squamous - mNSCLC - L2 - all population | |
| anti-PD-(L)1 | |||||
| atezolizumab based treatment | |||||
| atezolizumab alone | OAK ... POPLAR | OAK ... | |||
| avelumab based treatment | |||||
| avelumab alone | JAVELIN Lung 200 ... | JAVELIN Lung 200 ... | |||
| durvalumab based treatment | |||||
| durvalumab alone | ARCTIC ... | ||||
| durvalumab plus osimertinib | CAURAL ... | ||||
| nivolumab based treatment | |||||
| nivolumab alone | CheckMate 078 | CheckMate 057 | CheckMate 017 | ||
| pembrolizumab based treatment | |||||
| pembrolizumab alone | |||||
| pembrolizumab (10mg/kg) | KEYNOTE-010 ... KEYNOTE-010 ... | ||||
| pembrolizumab (2mg/kg) | KEYNOTE-010 ... KEYNOTE-010 ... | ||||
| Tislelizumab | RATIONALE 303 | ||||
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
